Sanofi SA Inhaber EO 2

FSNW

(FSE)

€ 65,00 <%= Resources.Global.txtDown %>

Opdateret 24-04-2018

Ændring %	-1,19%
Ændring	-0,78
Volume	2.968
Høj	€ 65,97
Lav	€ 65,00
Åben	€ 65,97
ISIN	FR0000120578
Seneste luk	€ 65,78
# af aktier	1.256,20M
Markedsværdi	81.653M EUR

I dag

Markedet er åbent (indtil 20:00) - Forsinket 15 min


Kursudvikling	Seneste	1 uge	1 måned	3 mdr	6 mdr	1 år

	65,00	-1,1%	1,7%	-9,9%	-18,5%	-23,4%

Dansk
Engelsk
Fondsbørsmeddelelser

	24 apr	Sanofi Head of Global R&D Elias Zerhouni to retire; Company names John Reed to take over on July 1

	17 apr	Advent International enters into exclusive negotiations to acquire Zentiva, Sanofi's European generics business

	12 apr	Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlemen...

	12 apr	Sanofi to invest €350 million in Canadian vaccine facility

	03 apr	Sanofi: EMA to review Dupixent® (dupilumab) as potential treatment for inadequately controlled moderate-to-severe asthma

	03 apr	Sanofi: EMA to review cemiplimab as a potential treatment for advanced cutaneous squamous cell carcinoma

	29 mar	Sanofi: EMA to review sotagliflozin as potential treatment for type 1 diabetes

	29 mar	Previously announced Tender Offers by Sanofi to acquire Ablynx will commence on April 4, 2018

	28 mar	Sanofi: Availability of the Pre-quarterly Results Communication

	15 mar	Sanofi successfully prices EUR 8 billion of bond issues

Flere nyheder

	Seneste	1 uge	1 måned	3 mdr	6 mdr	1 år	ÅTD

Konkurrenter

Abbott Laboratories	57,89	-2,7%	-2,7%	-8,4%	4,3%	32,3%	1,4%

Bristol-Myers Squibb Company	51,29	-1,9%	-17,4%	-19,3%	-19,9%	-4,9%	-16,3%

Eli Lilly and Company	81,38	2,1%	8,9%	-4,3%	-4,1%	0,2%	-3,6%

Merck & Company Inc (new)	59,53	1,0%	11,5%	-2,9%	-4,7%	-4,4%	5,8%

Pfizer Inc	36,86	1,0%	6,9%	-1,0%	1,9%	9,2%	1,8%

Astrazeneca PLC ORD SHS $0.25	4,946.50	-0,4%	3,3%	-1,0%	-2,5%	5,5%	-3,4%

Novartis NAM SF 0,50	62,64	-4,9%	-2,7%	-16,3%	-8,9%	-10,4%	-11,3%

Roche Hldg AG GEN	180,80	-0,6%	-2,3%	-8,3%	-7,7%	-24,0%	-14,1%

Glaxosmithkline PLC ORD 25P	1.400,00	-1,5%	6,4%	4,9%	-2,0%	-12,4%	5,9%

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. The company offers a diverse array of drugs with its highest revenue generator, Lantus, representing just over 10% of total sales. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent most of the remainder of sales.

Instrumenter	Kurs	Ændring
Abbott Labor..	57,89	-0,7%
Bristol-Myer..	51,29	-0,6%
Eli Lilly an..	81,38	1,6%
Merck & Comp..	59,53	-0,9%
Pfizer Inc	36,86	-0,5%
Astrazeneca ..	4,946.50	-0,9%
Novartis NAM..	62,64	-0,8%
Roche Hldg A..	180,80	-1,3%
Glaxosmithkl..	1.400,00	-4,3%

Sanofi SA Inhaber EO 2

Nyheder om Sanofi SA Inhaber EO 2

Relaterede

Sanofi SA Inhaber EO 2

Nyheder om Sanofi SA Inhaber EO 2

Relaterede

Firmaprofil

Peers